Darolutamide, enzalutamide, and apalutamide in Non-metastatic Castration-Resistant Prostate Cancer

Advanced Prostate Cancer Consensus Conference shared a post on LinkedIn:

“Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer Out in JAMA Network Open

This retrospective cohort study compared the clinical use and outcomes of  3 androgen receptor inhibitors (ARIs)—darolutamide, enzalutamide, and apalutamide in nonmetastatic castration-resistant Prostate Cancer (nmCRPC).

Data from 870 patients showed that darolutamide had lower⬇️rates of treatment discontinuation and progression to metastatic CRPC (mCRPC) compared to enzalutamide and apalutamide. After adjusting for covariates, darolutamide demonstrated a significant risk reduction in these outcomes.

These findings suggest that darolutamide may offer better tolerability and clinical effectiveness than the other ARIs, highlighting the need for further comparative studies in the absence of head-to-head trials.”

Androgen Receptor Inhibitors in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Authors: Daniel J. George, Alicia K. Morgans, Niculae Constantinovici,  Nasreen Khan,  Javeed Khan, Guifang Chen, Vlasta Hlebec, Neal D. Shore.

Source: Advanced Prostate Cancer Consensus Conference/LinkedIn